RVX ANNOUNCES TYPE C MEETING WITH FDA FOR CORAL, A PHASE 3 HIGH-RISK COVID-19 OUTPATIENT STUDY posted on May 09, 2022 07:42AM Log in to use the IP Check tool [?]